{"url_path":"/sec/eikn/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1861123/0001193125-26-249725-index.html","accession_number":"0001193125-26-249725","cik":"0001861123","ticker":"EIKN","issuer_name":"Eikon Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1861123/0001193125-26-249725-index.html","primary_entity_key":"0001861123","primary_entity_name":"Eikon Therapeutics, Inc."},"word_count":92,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn May 30, 2026, the Company issued a press release announcing updated data on its Phase 2 trial of EIK1001 in first-line patients with stage 4 non-small cell lung cancer and new and updated data on its Phase 1/2 trial of EIK1003 in patients with advanced solid tumors, which were presented at the 2026 American Society of Clinical Oncology Annual Meeting. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference."}